Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Net Cash Flow: 2020-2024

Historic Net Cash Flow for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to -$47.4 million.

  • SAB Biotherapeutics' Net Cash Flow rose 417.41% to $25.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.4 million, marking a year-over-year increase of 204.76%. This contributed to the annual value of -$47.4 million for FY2024, which is 214.28% down from last year.
  • Latest data reveals that SAB Biotherapeutics reported Net Cash Flow of -$47.4 million as of FY2024, which was down 214.28% from $41.5 million recorded in FY2023.
  • SAB Biotherapeutics' 5-year Net Cash Flow high stood at $41.5 million for FY2023, and its period low was -$47.4 million during FY2024.
  • Its 3-year average for Net Cash Flow is -$10.1 million, with a median of -$24.5 million in 2022.
  • In the last 5 years, SAB Biotherapeutics' Net Cash Flow skyrocketed by 329.96% in 2021 and then plummeted by 214.28% in 2024.
  • Over the past 5 years, SAB Biotherapeutics' Net Cash Flow (Yearly) stood at $6.3 million in 2020, then surged by 329.96% to $26.9 million in 2021, then crashed by 190.95% to -$24.5 million in 2022, then spiked by 269.40% to $41.5 million in 2023, then crashed by 214.28% to -$47.4 million in 2024.